Publications

Liste des publications de l'année 2017

Articles

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).

Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O.

Dig Liver Dis. 2017 Aug;49(8):831-840

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label,randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L; Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED0), Société Française de Radiothérapie Oncologique (SFRO).

Dig Liver Dis. 2017 Apr;49(4):359-367

Abstracts

ASCO 2017

Oxaliplatin-based chemotherapy for patients with stage III colon cancer: Disease Free Survival results of the three versus six months adjuvant IDEA France Trial.

Thierry Andre, Franck Bonnetain, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Jérôme Dauba, Dewi Vernerey, Nasredine Aissat, Christophe Louvet, Céline Lepère, Olivier Jean Marie Dupuis, Yves Becouarn, May Mabro, Joëlle Egreteau, Olivier Bouche, Gael Deplanque, Marc Ychou, Aimery De Gramont, Julien Taieb, GERCOR, FFCD, and UNICANCER (PRODIGE)

Oral presentation; Abstract: 3500; Citation: J Clin Oncol 35, 2017 (suppl; abstr 3500)

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Qian Shi, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson; Mayo Clinic Cancer Center, Rochester, MN; IRCCS San Martino - IST, Genoa, Italy; Wayne State University, Karmanos Cancer Institute, Detroit, MI; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital, Chiba, Japan; University of Glasgow, Cancer Research UK Clinical Trials Unit, Glasgow, United Kingdom; Hopital Européen Georges Pompidou, Paris, France; University of Heraklion, Athens, Greece; University of Oxford, Oxford, United Kingdom; Ospedale Papa Giovanni XXIII, Bergamo, Italy; Dana-Farber Cancer Institute, Boston, MA; Methodology and Quality of Life Unit, Department of Oncology, INSERM UMR 1098, University Hospital of Besancon; French National Platform Quality of Life and Cancer, Besançon, France; Department of Surgical Oncology and Vascular Surgery, the University of Tokyo, Tokyo, Japan; Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece; Mayo Clinic, Rochester, MN; Duke University, Durham, NC; IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy; Medical Oncology Department, Saint-Antoine Hospital, Paris, France; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom)

Plenary Session ; Abstract: LBA1; Citation: J Clin Oncol 35, 2017 (suppl; abstr LBA1)

ASCO GI 2017

Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

J. Taieb F. Bonnetain L. Mineur J. Bennouna J. Desrame R. Faroux S. Fratte J. Dauba D. Vernerey C. Louvet

Abstract: A473O; Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

Olivier Dubreuil , Jean Baptiste Bachet , Pascal Hammel , Jerome Desrame , Aurelia Meurisse , Thierry Andre , Philippe Debourdeau , Jérôme Dauba , Thierry Lecomte , Jean Francois Seitz , Christophe Tournigand , Thomas Aparicio , Véronique Guerin Meyer , Julien Taïeb , Sandrine Hiret , Julien Volet , Amandine Monier , Benoist Chibaudel , Franck Bonnetain , Christophe Louvet ;

Abstract:350, Journal of Clinical Oncology 35, no. 4_suppl (February 2017) 350-350.

Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.

Antoine Schernberg, Dewi Vernerey, David Goldstein, Jean Luc Van Laethem, Bengt Glimelius, Paul Van Houtte, Franck Bonnetain, Christophe Louvet, Pascal Hammel, Florence Huguet

Abstract: 4120; Citation: J Clin Oncol 35, 2017 (suppl; abstr 4120)

AACR 2017

Impact of circulating and tissue biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II Study

Annemilai Tijeras-Raballand, Armand de Gramont, Marielle Chiron, Jean-Baptiste Bachet, Thierry Andre, Dominique Auby, Jerome Desramé, Baba-Hamed Nabil, Lecaille Cedric, Valérie Lebrun, Christophe Louvet, Annette Larsen, Christophe Tournigand, Sylvie Benner, Malika Attia, Aimery de Gramont, Franck Bonnetain and Benoist Chibaudel

Abstract 2734: July 2017 Volume 77, Issue 13 Supplement

ESMO 2017

Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)

S. Kim (Besançon, France) E. Francois (Nice, France) F. Bidard (Paris, France) E. Samalin (Montpellier, France) F. El Hajbi (Lille, France) N. Baba-Hamed (Paris, France) S. Dumont (Paris, France) S. Pernot (Paris, France) D. Peiffert (Nancy, France) F. Ghiringhelli (Dijon, France) O. Bouche (Reims, France) J. Desrame (Lyon, France) M. Zoubir (Paris, France) A. Parzy (Caen, France) D. Smith (Bordeaux, France) C. De la Fouchardiere (Lyon, France) B. Buecher (Paris, France) V. Vendrely (Bordeaux, France) F. Bonnetain (Besançon, France) C. Borg (Besançon, France)

Poster: 536P

CONTACTS

GERCOR
151 rue du Faubourg Saint-Antoine
75011 Paris
Téléphone : + 33 1 40 29 85 00
Télécopie : + 33 1 40 29 85 08
Email : gercor@gercor.com.fr
Le GERCOR en tant que Groupe
Coopérateur est membre des GCO